475479-34-6

Usage

InChI:InChI=1/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1

Upstream product

• 475479-24-4 2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid 
• 475480-89-8 (S)-4-benzyl-3-((S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionyl)-oxazolidin-2-one 
• 849150-55-6 (Z)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-acrylic acid 

Downstream Products

• 849150-56-7 (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid (S)-phenyl ethylamine salt 
• 1578246-97-5 diisopropylammonium (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propanoate 
• 881663-41-8 (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid L-norephedrine salt 

Relevant academic research and scientific papers

SOLID STATE FORMS OF ALEGLITAZAR SODIUM

The present invention provides solid state forms of Aleglitazar sodium, processes for preparing the solid state forms, and pharmaceutical compositions comprising the solid state forms.

PROCESS FOR THE PREPARATION OF PROPIONIC ACID DERIVATIVES

The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof, by hydrogenation of a compound of formula (II).

PROCESS FOR THE PREPARATION OF PROPIONIC ACID DERIVATIVES

The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof.

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.

Process for the production of chiral propionic acid derivatives

The present invention is concerned with a novel process for the preparation of compounds of formula I comprising catalytic asymmetric hydrogenation of a compound of formula (II) in the presence of a catalyst comprising ruthenium and a chiral diphosphine ligand or comprising rhodium and a chiral diphosphine ligand, wherein R1, R2, R3 and R4 are as defined in the specification and claims. The compounds of formula I and the corresponding salts and/or esters are pharmaceutically active substances.

Oxazole derivatives

The present invention relates to novel oxazole compounds which act as PPARα and PPARγ agonists and are accordingly useful for the treatment of diseases modulated by PPARα and PPARγ such as diabetes.